Flood victims to benefit from free medical consultation and prescription medication.
KUALA LUMPUR, Malaysia, Dec. 29, 2021 /PRNewswire/ — Amidst Malaysia's worst flash flooding following heavy rains over the weekend that displaced tens of thousands of people, Malaysia's first and largest digital health platform, DoctorOnCall, has announced a flood relief medical assistance initiative.
As part of the initiative, DoctorOnCall will provide free medical consultation to Malaysians who have been affected and in need of health care as a result of the recent floods. Medication up to a maximum amount of RM80 will also be dispensed for patients upon doctors' prescription and discretion.
With Selangor, Pahang, Kelantan and Johor being the worst affected by the floods, many roads remain washed out leaving a number of people stranded while waiting for the waters to subside and basic utilities such as water and electricity to return. Thousands of flood victims face a huge mobility issue as their vehicles were badly damaged during the flood. It is estimated at least 50,000 vehicles were damaged throughout these flood areas. This has caused many victims to be unable to visit nearest hospitals or clinics should they need medical attention.
Hazwan Najib, Director and Co-Founder of DoctorOnCall said: "In response to the communities' plight, DoctorOnCall is ready to render assistance, offering a helping hand to flood victims who require medical attention. We will provide free consultation and critical medications to patients, ensuring our medical services are fast, efficient, orderly and effective, giving priority to those with known medical conditions, accessibility issues and people with disabilities. Using the DoctorOnCall telehealth platform, flood victims will be able to consult with our registered doctors virtually."
DoctorOnCall has also mobilised a team of volunteers including Doctors and Nurses in several affected areas to provide mobile on-site medical support including medications, testing for COVID-19, Dengue and other illnesses and wound care if needed by displaced victims.
DoctorOnCall encourages Malaysians to apply for the Merchantrade Insure Life, a life insurance policy that covers death from any cause, including COVID-19. The policy's payout amount is doubled to RM40,000 in the event of particular illnesses such as dengue fever, chikungunya fever, malaria, Japanese Encephalitis, Avian influenza, or the Zika virus.
"As the water recedes, we can anticipate an increase in flood-related infectious diseases and health conditions such as diarrhea, food poisoning and malaria. Some victims may even have preexisting medical conditions such as diabetes, hypertension and even heart problems with a lot of their medical records, medical cards and the medication lost in flood. It is at times like this that a good insurance policy gives us some peace of mind. Investing in comprehensive life insurance will ensure that you are covered throughout medical emergencies and do not have to compromise on the quality of treatments," he continued.
The Merchantrade Insure Life plan can be redeemed using the RM50 Perlindungan Tenang Voucher (PTV) which enables eligible Malaysians aged 18 to 60 years old who are currently recipients of Bantuan Prihatin Rakyat (BPR) to benefit from the policy coverage with a sum insured of RM20,000 for a year.
The PTV is significant as it empowers Malaysians, especially those who still do not have life insurance coverage to take measures to financially protect members of their families. The aim is to provide simple and affordable microinsurance products to the unserved and underserved segments in Malaysia.
Malaysians who wish to apply for DoctorOnCall's free flood relief medical assistance can do so via this link:
About DoctorOnCall
DoctorOnCall is Malaysia's first online Medical Video-consultation platform that combines advanced Video and voice. DoctorOnCall provides fast, easy and cost-effective access to Malaysia's top doctors and other healthcare providers in the country. Our patients can have Medical Video visits on their smartphones or computers at any time of day and anywhere. We do this without making any sacrifice on quality as our medical and mental health professionals are carefully screened and trained to conduct Medical Video-consultations.

We believe that the future of healthcare is digital and together with our medical and mental health providers will provide you with better healthcare service at a more affordable cost.

For more information, visit us at https://www.doctoroncall.com.my/
SOURCE DoctorOnCall
There’s no other way of putting it, Monday was a horrible day to be a BridgeBio Pharma (BBIO) investor. Shares cratered by 72% after a late-stage study of a heart disease drug went awry. Specifically, the company reported results from the Phase 3 trial of acoramidis for the treatment of patients with transthyretin amyloid cardiomyopathy, a condition in which the heart sees an increase of abnormal protein. The drug failed at the primary endpoint of a 6-minute walk test following 12 months of trea
Texas Children's Hospital Center for Vaccine Development began working on a SARS vaccine in 2011 and used the critical scientific information they compiled then to develop a vaccine for the virus that causes Covid-19.
AbbVie's immunology drug Skyrizi could soon be approved in the European Union to treat patients with Crohn's disease.
It might be time to step up from cloth if you're in an area with high transmission.
Is Pfizer stock a buy after the FDA authorized its Covid pill regimen for emergency use? Is PFE stock a buy right now?
Let's be clear—when I say serious results, I'm not talking about weight. I guess I should note I did lose some—a mere three pounds. But the "serious results" I saw when giving up alcohol for an entire month was a complete improvement of my physical and mental health. And it was motivating enough for me to drink significantly less than I once was.I admit, I was one of those people during the pandemic that turned to alcohol in times of stress. I wouldn't say to an unhealthy degree; a glass of wine
Monday was a very good day for stocks in general, but it was a standout day for healthcare diagnostics specialist Cue Health (NASDAQ: HLTH). On its website, Cue Health isn't shy to point out that it's the maker of the first molecular diagnostic test for COVID-19 approved by the U.S. Food and Drug Administration (FDA). Cue Health's COVID diagnostic test is also a product that can be administered at home with no training.
CHICAGO — With another surge in COVID-19 cases making more Illinoisans sick and once again crowding hospitals, Gov. J.B. Pritzker on Monday announced the state will more than double its staffing at vaccination sites to ensure that more people get inoculated and to meet the demand for booster shots. The move comes as the omicron variant has taken shape throughout the country and the state, …
The tough talk has not moved the needle and, if anything, has made resistance more resolute, Alain Pinel writes.
Shares of Bridgebio Pharma (NASDAQ: BBIO), a clinical-stage biotechnology company, are getting crushed after the company reported a disappointing trial failure. Acoramidis is an experimental treatment that stabilizes a transport protein called transthyretin before it breaks up and leads to heart damage. Bridgebio Pharma stock is tanking today because a phase 3 trial with acoramidis and transthyretin mediated cardiomyopathy (ATTR-CM) patients suggests it doesn't improve outcomes nearly as well as the competition.
A group of nearby homeowners who said their houses were destroyed by the fire had filed a lawsuit against Exxon. An Exxon spokesperson told Reuters the company was reviewing the order. "The Baytown Refinery will not be fully restored to service until safe to do so," the spokesperson said.
Following reports of multiple COVID-19 outbreaks aboard cruise ships, one senator is calling on public-health officials to pause sailings once again. Sen. Richard Blumenthal, a Democrat from Connecticut, posted on Twitter (TWTR) an appeal to the Centers for Disease Control and Prevention to halt cruising temporarily amid the latest phase of the coronavirus pandemic. “Cruises are repeating recent history as petri dishes of COVID infection,” he wrote.
The Companies Are Committed To Providing Timely Access to Molnupiravir Through Comprehensive Supply and Access Approach
Power outage also reported in neighbourhood around crash site
CDC cuts Covid isolation times in half, flight cancellations continue, and other news to start your day.
Shares of BridgeBio Pharma Inc. plummeted 66.2% in premarket trading Monday, after the drug maker said a Phase 3 study of its acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) failed to meet its primary endpoint at Month 12. The company said the decline observed in both arms of the study was similar to expected functional decline in healthy elderly adults, and were also "substantially less" than declines observed in previous untreated arms reviewed
Yahoo Finance's Anjalee Khemlani details the CDC's revisions to its COVID-19 guidelines regarding quarantine procedures for exposed individuals, including reduced isolation time, in addition to highlighting the testing kit scarcity and Dr. Fauci's latest recommendations for air travel.
Thousands and flights were canceled on Christmas Eve and Christmas Day. Hundreds more were canceled on Monday.
The lawsuit stems from a 2005 agreement between Gilead, Royalty Pharma and Emory University around emtricitabine, which is an important part of Gilead's multibillion-dollar HIV franchise.
Sentia is made from plant extracts that can mimic the effects of alcohol, and is meant to top out around the feeling of having a glass or two of wine. The company’s founders don’t yet have enough evidence to legally make claims about their products’ health effects, but the implication is clear: synthetic alcohol could capture the good parts of drinking while ditching the death and disease associated with it. Things that sound too good to be true usually are, says Dr. Anna Lembke, medical director of addiction medicine at Stanford University School of Medicine and author of Dopamine Nation.